Login / Signup

Immunotherapy in gynecological cancers.

Domenica LorussoValentina CeniGennaro DanieleAntonella PietragallaVanda SalutariMargherita MuratoreCamilla NeroFrancesca CiccaroneGiovanni Scambia
Published in: Exploration of targeted anti-tumor therapy (2021)
Immunotherapy has changed the natural history of several malignancies that, a decade ago, had a very poor prognosis, such as lung cancer and melanoma. Consequently, many attempts have been done to expand the indications of immunotherapy agents, predominantly immune checkpoint inhibitors (ICIs), in other cancers, including gynecological malignancies. Alongside promising results in cervical and endometrial neoplasms, there are not clear data on the benefit of ICIs as single agent or in combination with antiangiogenic agents in ovarian cancer (OC) and ongoing trials are focusing on combining ICIs with standard chemotherapy or PARP inhibitors. This chapter summarized the evidences of ICIs in gynecological malignancies and report the ongoing trials in cervical, endometrial and OC.
Keyphrases
  • poor prognosis
  • long non coding rna
  • endometrial cancer
  • dna damage
  • dna repair
  • locally advanced
  • squamous cell carcinoma
  • radiation therapy
  • young adults
  • rectal cancer
  • artificial intelligence
  • deep learning